AP24534: an orally active kinase inhibitor that targets multiple pro-angiogenic receptors and exhibits potent anti-tumor activity in vivo

被引：0
|
作者：
Rivera, V. M.
DiRenzo, R.
Berk, L.
Wardwell, S.
Ning, Y.
Narasimhan, N. I.
Xu, Q.
Shakespeare, W. C.
Wang, F.
Clackson, T.
机构：
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72487-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 28 条
  • [1] The orally active kinase inhibitor AP24534 has potent activity against the FGF receptor family in multiple cancer models
    Gozgit, Joseph
    Wong, Matthew
    Berk, Lori
    Wardwell, Scott
    Jang, Hyun Gyung
    Narasimhan, Narayana
    Shakespeare, William
    Wang, Frank
    Clackson, Tim
    Rivera, Victor
    CANCER RESEARCH, 2009, 69
  • [2] Potent antitumor activity of AP24534, ad orally active inhibitor of ber-abl variants including T3154, in In vitro and in vivo models of chronic myeloid leukemia (CML)
    Rivera, Victor M.
    Xu, Qihong
    Wang, Frank
    Snodgrass, Joseph
    O'Hare, Thomas
    Corbin, Amie S.
    Keats, Jeffrey
    Lamore, Sarah
    Ning, Yaoyu
    Wardwell, Scott
    Russian, Karin
    Broudy, Marc
    Shakespeare, William C.
    Druker, Brian J.
    Iuliucci, John D.
    Clackson, Tim
    BLOOD, 2007, 110 (11) : 312A - 313A
  • [3] Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)
    Rivera, Victor M.
    Xu, Qihong
    Berk, Lori
    Keats, Jeffrey
    Wardwell, Scott
    Wang, Frank
    Shakespeare, William C.
    Clackson, Tim
    BLOOD, 2008, 112 (11) : 1008 - 1009
  • [4] DISCOVERY OF POTENT, ORALLY ACTIVE COMPOUNDS OF TYROSINE KINASE AND SERINE/THREONINE-PROTEIN KINASE INHIBITOR WITH ANTI-TUMOR ACTIVITY IN PRECLINICAL ASSAYS
    Qiu, Yun-Qing
    Zhou, Jue
    Kang, Xin-Shan
    Shen-Tu, Jian-Zhong
    Ding, Lie-Ming
    Tan, Fen-Lai
    Guo, Jing
    Li, Lan-Juan
    AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES, 2012, 9 (03) : 431 - 439
  • [5] GW786034: A pan inhibitor of VEGF receptors with potent anti-tumor and anti-angiogenic activity.
    Kumar, R
    Knick, VB
    Rudolph, SK
    Johnson, JH
    Crosby, RM
    Hopper, TM
    Miller, CG
    Harrington, LE
    Onori, JA
    Mullin, RJ
    Gilmer, TM
    Truesdale, AT
    Epperly, AH
    Bolor, A
    Cheung, M
    Stafford, JA
    Luttrell, DK
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8968S - 8968S
  • [6] Preclinical development of a novel oral multitargeted kinase inhibitor with potent in vivo anti-tumor activity
    Beaulieu, Normand
    Dupont, Isabelle
    Hannah Nguyen
    Carole, Beaulieu
    Ste-Croix, Helene
    Robert, Marie-France
    Lefebvre, Sylvain
    Lu, Ai Hua
    Dubay, Maria
    Rahil, Gabi
    Wang, James
    Mannion, Michael
    Raeppel, Stephane
    Saavedra, Oscar
    Claridge, Stephen
    Isakovic, Lubo
    Zhan, Lijie
    Gaudette, Frederic
    Zhou, Nancy
    Nantel, Miguel
    Raeppel, Franck
    Vaisburg, Arkadii
    Besterman, Jeffrey
    Maroun, Christiane
    CANCER RESEARCH, 2009, 69
  • [7] Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
    Liang, Chris
    Yuan, Xiaobin
    Shen, Zhilin
    Wang, Yang
    Ding, Lieming
    MOLECULAR THERAPY-ONCOLYTICS, 2022, 24 : 577 - 584
  • [8] TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo
    Liang, Apeng
    Dong, Shengli
    Liu, Guangbin
    Guo, Zhengfei
    Li, Meihua
    Han, Shuaibo
    Cao, Yundi
    Tu, Yian
    Zhou, Chao
    Yu, Yu
    Xiao, Linglin
    Huang, Wei
    Yang, Xinlong
    Fang, Lian
    Li, Haoyun
    Niu, Chengshan
    Jiang, Mingyu
    Xing, Feng
    Chen, Shaoqing
    Li, Jun
    Wu, Yusheng
    CANCER RESEARCH, 2023, 83 (07)
  • [9] AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation
    Lyons, John F.
    Grimshaw, Kyla M.
    Woodhead, Steven J.
    Feltell, Ruth E.
    Reule, Matthias
    Smyth, Tomko
    Seavers, Lisa C.
    Harada, Isobelle
    Higgins, Jacqueline
    Smith, Donna M.
    Fazal, Lynsey
    Workman, Paul
    Collins, Ian
    Garrett, Michelle D.
    Thompson, Neil T.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3512S - 3512S
  • [10] Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer
    Wang, Shunyou
    Lan, Lucy
    Janes, Mathew
    Jessen, Katti
    Kessler, Linda
    Kucharski, Jeff
    Guo, Xin Xin
    Staunton, Jocelyn
    Elia, Marikka
    Banerjee, Urmi
    Stewart, Josh
    Dartania, Levan
    Li, Liansheng
    Chan, Katrina
    Martin, Mike
    Ren, Pingda
    Rommei, Christian
    Liu, Yi
    CANCER RESEARCH, 2012, 72
123